Companies 0 See All

Hedge Funds 0 See All

Insiders 0 See All

Institutional Investors 0 See All

Click here to see all results for

Home > Insider Trading > Filing (0001493152-22-017630)

Filing Details

Accession Number:: 0001493152-22-017630
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2022-06-23 18:54:04
Reporting Period:: 2022-06-21

Accepted Time:: 2022-06-23 18:54:04
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1394319	Tracon Pharmaceuticals Inc.	TCON	Biological Products, (No Disgnostic Substances) (2836)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1595855	Opaleye Management Inc.	One Boston Place, 26Th Floor Boston MA 02108		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, Par Value $0.001 Per Share	Acquisiton	2022-06-21	841,989	$1.31	3,776,589	No	4	P	Indirect	By Opaleye, L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By Opaleye, L.P.

Reported Derivative Holdings

Show Other Fields >>

Sec. Name	Sec. Type	Price	Date	Expiration Date	Amount	Remaning Holdings	Nature of Ownership
Common Stock	Prefunded Warrants	$0.01	2020-08-27	2030-08-27	1,889,513	1,889,513	Indirect
Common Stock	Prefunded Warrants	$0.01	2020-08-31	2030-08-31	1,358,593	1,358,593	Indirect
Common Stock	Prefunded Warrants	$0.01	2022-06-21	2032-06-21	2,205,018	2,205,018	Indirect

Expiration Date	Amount	Remaning Holdings	Nature of Ownership
2030-08-27	1,889,513	1,889,513	Indirect
2030-08-31	1,358,593	1,358,593	Indirect
2032-06-21	2,205,018	2,205,018	Indirect

Footnotes

Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management Inc. may be deemed to beneficially own the securities owned directly by the Fund.
The warrants may not be exercised to the extent that such exercise would cause the reporting person and its affiliates to beneficially own more than 19.99% of the issuers then outstanding shares.